MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Net Debt 2011-2026 | AMPH
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 457 M | 457 M | 449 M | -80.5 M | -48.8 M | -57 M | -26.6 M | -36.1 M | -18.4 M | -34.6 M | -25 M | -24.1 M | -21.4 M | -12.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 457 M | -80.5 M | 69.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
NextCure
NXTC
|
-20.8 M | $ 12.67 | 0.52 % | $ 354 M |  USA |
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Liquidia Corporation
LQDA
|
-72.5 M | $ 34.25 | -0.38 % | $ 2.23 B | USA |
 |
Shattuck Labs
STTK
|
-51.8 M | $ 5.02 | 6.13 % | $ 214 M | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
AbCellera Biologics
ABCL
|
14.7 M | $ 3.58 | -1.38 % | $ 1.07 B |  Canada |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
-17.2 M | $ 15.57 | -5.89 % | $ 3.71 B | USA |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
-46 M | $ 14.19 | -1.18 % | $ 208 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
166 M | $ 75.6 | -1.22 % | $ 1.46 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
-311 M | $ 20.24 | 1.91 % | $ 2.55 B | USA |
 |
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.5 | -8.28 % | $ 383 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-48 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-205 M | $ 159.87 | -2.57 % | $ 7.95 B | USA |
 |
BridgeBio Pharma
BBIO
|
1.44 B | $ 65.73 | -1.22 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 2.72 | -3.31 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
-1.3 B | $ 60.54 | 0.18 % | $ 11.6 B | USA |
 |
Burford Capital Limited
BUR
|
-135 M | $ 8.26 | -1.31 % | $ 1.36 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | USA |
 |
Codexis
CDXS
|
12.5 M | $ 1.25 | 16.2 % | $ 91.8 M | USA |
 |
Cabaletta Bio
CABA
|
-188 M | $ 3.2 | -6.71 % | $ 3.74 M | USA |